Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) (TALC)
Asthma

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria for TALC and BASALT Studies:
- Clinical history consistent with asthma
- Forced expiratory volume in one second (FEV1) greater than 40% of predicted value
Asthma confirmed by one of the following two criteria:
- Beta-agonist reversibility to 4 puffs albuterol of at least 12% OR
- Methacholine provocative concentration at 20% (PC20) of 8 milligrams per milliliter (mg/mL) or less when not on an inhaled corticosteroid (ICS), or 16 mg/mL or less when on an ICS
Need for daily controller therapy (i.e., ICS, leukotriene modifiers, and/or long-acting beta-agonists) based on one or more of the following criteria:
- Received prescription for or used asthma controller within the 12 months prior to study entry OR
- Experienced symptoms for more than twice a week and not on asthma controller
- If on inhaled steroids (any drug at any dose not exceeding the equivalent of 1000 micrograms (mcg) of fluticasone daily), participant must have been on a stable dose for at least 2 weeks prior to study entry
- Non-smoker (i.e., total lifetime smoking history less than 10 pack-years; no smoking for at least 1 year prior to study entry)
- Willing to use an effective form of birth control throughout the study
Inclusion Criteria for TALC Study:
- Ability to measure morning (AM) peak expiratory flow (PEF) on schedule using electronic peak flow meter (EPFM) and to complete the study diary correctly at least 75% of the time during the interval between Weeks 2 and 4 of the run-in period
- Adherence with study medication dosing at least 75% of the time during the interval between Weeks 2 and 4 of the run-in period
- No asthma exacerbation requiring use of oral corticosteroids or additional asthma medications (including an increased dose of ICS) during the run-in period
- FEV1 greater than 40% of the predicted value
Exclusion Criteria for BASALT and TALC Studies:
- Lung disease other than asthma, including chronic obstructive pulmonary disease (COPD) and chronic bronchitis
- Established or suspected diagnosis of vocal cord dysfunction
- Significant medical illness other than asthma
- History of respiratory tract infection within the 4 weeks prior to study entry
- History of a significant asthma exacerbation within the 4 weeks prior to study entry
- History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the 5 years prior to study entry
- Hyposensitization therapy other than an established maintenance regimen
- Inability to coordinate use of the delivery devices used in the study, based on the opinion of the investigator or clinical coordinator
- Pregnant
Exclusion Criteria for TALC Study:
- Inability to coordinate use of the medication delivery devices used in the study, based on the opinion of the investigator or clinical coordinator
- Presence at Week 4 of the run-in period of any of the exclusion criteria stipulated for Week 0 of the run-in period (Note: Respiratory tract infections that do not cause the participant to meet exacerbation criteria are not considered exclusionary.)
Sites / Locations
- University of California, San Diego
- University of California, San Francisco
- National Jewish Medical and Research Center
- Brigham & Women's Hospital
- Washington University, St. Louis
- Columbia University Health Sciences
- Duke University Medical Center
- Wake Forest University Health Sciences
- University of Texas Medical Branch
- University of Wisconsin, Madison
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Tio + 1xICS || LABA + 1xICS || 2xICS
TIO + 1xICS || 2xICS || LABA + 1xICS
LABA + 1xICS || Tio + 1xICS || 2xICS
LABA + 1xICS || 2xICS || Tio + 1xICS
2xICS || Tio + 1xICS| || LABA + 1xICS
2xICS || LABA + 1xICS || Tio + 1xICS
Participants will take part in three 16-week treatment periods, which will occur in the following order: tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) beclomethasone dipropionate 160 mcg twice daily (2xICS) Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
Participants will take part in three 16-week treatment periods, which will occur in the following order: tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) beclomethasone dipropionate 160 mcg twice daily (2xICS) salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
Participants will take part in three 16-week treatment periods, which will occur in the following order: salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) beclomethasone dipropionate 160 mcg twice daily (2xICS) Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
Participants will take part in three 16-week treatment periods, which will occur in the following order: salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) beclomethasone dipropionate 160 mcg twice daily (2xICS) tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
Participants will take part in three 16-week treatment periods, which will occur in the following order: beclomethasone dipropionate 160 mcg twice daily (2xICS) tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
Participants will take part in three 16-week treatment periods, which will occur in the following order: beclomethasone dipropionate 160 mcg twice daily (2xICS) salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS) Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).